Impact of age, bilirubin, and disease burden in unresectable pancreatic cancer patients receiving first-line chemotherapy: A population-based analysis

Date

08 Oct 2016

Session

Poster Display

Presenters

Ying Wang

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

Y. Wang1, P. Camateros2, W. Cheung1

Author affiliations

  • 1 Medical Oncology, British Columbia Cancer Agency, V5Z4E6 - Vancouver/CA
  • 2 Medicine, University of British Columbia, V5Z1M9 - Vancouver/CA
More

Resources

Background

FOLFIRINOX (FFN), nab-paclitaxel plus gemcitabine (NG), and gemcitabine (gem) are 3 systemic therapies that provide clinically meaningful benefit to patients with unresectable pancreatic cancer (UPC). Clinical trials have previously excluded patients with advanced age, elevated bilirubin, or locally advanced disease. Our aim was to examine whether age, bilirubin, and disease extent affected treatment outcomes.

Methods

Patients diagnosed with UPC who initiated palliative chemotherapy from August 2014 to August 2015 at any 1 of 5 cancer centers in British Columbia were identified from the provincial pharmacy. Clinical, pathological, treatment, and outcome characteristics were compared.

Results

150 patients were included: 53% men, 78% ECOG 0/1, and 71% with metastatic disease. Patients who received FFN and NG were younger (p 

Conclusions

Receipt of FFN and NG portended a better prognosis than gem alone. In the absence of a randomized comparison of all 3 regimens, our population-based study revealed that the introduction of modified FFN and NG confers real world effectiveness for UPC patients regardless of age and bilirubin at presentation.

Clinical trial identification

N/A

Legal entity responsible for the study

Ying Wang

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings